Walleye Capital
ALLO icon

Walleye Capital’s Allogene Therapeutics ALLO Stock Holding History

Walleye Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,800
Closed -$18.9K – 4825
2023
Q2 		$18.9K Buy
+3,800
New +$20.6K ﹤0.01% 3812
2019
Q2 		– Sell
-9,000
Closed -$260K – 1694
2019
Q1 		$260K Buy
+9,000
New +$261K 0.04% 655

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Walleye Capital's ALLO Position: Q2 2026 in Review

Walleye Capital opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 3,268,012 shares worth $6.8M. The stake represents 0.02% of the portfolio and ranks #655 among its holdings. This is a return to the name: Walleye Capital previously reported a position in ALLO as recently as Q4 2023.

Walleye Capital first reported a position in ALLO in Q2 2020 and has held it in 5 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Walleye Capital held 3,268,012 shares of Allogene Therapeutics worth $6.8M as of Q2 2026.
  • Allogene Therapeutics was a new Walleye Capital position in Q2 2026.
  • Allogene Therapeutics made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #655 holding.
  • Walleye Capital first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 5 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.